Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Arcus Biosciences Inc (NYSE: RCUS) was $9.43 for the day, down -1.87% from the previous closing price of $9.61. In other words, the price has decreased by -$1.87 from its previous closing price. On the day, 0.54 million shares were traded. RCUS stock price reached its highest trading level at $9.925 during the session, while it also had its lowest trading level at $9.26.
Ratios:
Our analysis of RCUS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.37 and its Current Ratio is at 5.37. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 27 ’25 when KANEKO YASUNORI bought 20,000 shares for $10.06 per share. The transaction valued at 201,200 led to the insider holds 28,400 shares of the business.
ROSEN TERRY J bought 19,800 shares of RCUS for $201,465 on Feb 27 ’25. The Chief Executive Officer now owns 2,554,160 shares after completing the transaction at $10.18 per share. On Feb 18 ’25, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 1,363,636 shares for $11.00 each. As a result, the insider paid 14,999,996 and bolstered with 31,424,760 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 998495552 and an Enterprise Value of 82496848. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.08 while its Price-to-Book (P/B) ratio in mrq is 1.88. Its current Enterprise Value per Revenue stands at 0.585 whereas that against EBITDA is -0.194.
Stock Price History:
The Beta on a monthly basis for RCUS is 0.90, which has changed by -0.3997454 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $18.98, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is 3.38%, while the 200-Day Moving Average is calculated to be -19.71%.
Shares Statistics:
RCUS traded an average of 1.07M shares per day over the past three months and 722380 shares per day over the past ten days. A total of 105.90M shares are outstanding, with a floating share count of 64.64M. Insiders hold about 38.95% of the company’s shares, while institutions hold 61.83% stake in the company. Shares short for RCUS as of 1752537600 were 10054835 with a Short Ratio of 9.43, compared to 1749772800 on 10473800. Therefore, it implies a Short% of Shares Outstanding of 10054835 and a Short% of Float of 14.56.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
